TheraCryf (FRA:8EV) Research & Development : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TheraCryf's Research & Development for the six months ended in Sep. 2023 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

TheraCryf Research & Development Historical Data

The historical data trend for TheraCryf's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Research & Development Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Research & Development

Get a 7-Day Free Trial

1.97

1.90

2.34

1.73

3.78

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Research & Development	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

TheraCryf (FRA:8EV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TheraCryf Research & Development Related Terms

Thank you for viewing the detailed overview of TheraCryf's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines